Abnormal salivary total and oligomeric alpha-synuclein in Parkinson's disease

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Vivacqua, Giorgio ^a,b   Latorre, Anna ^a   Suppa, Antonio ^a,c   Nardi, Michela ^a   Pietracupa, Sara ^a   Mancinelli, Romina ^b   Fabbrini, Giovanni ^a,c   Colosimo, Carlo ^a   Gaudio, Eugenio ^b   Berardelli, Alfredo ^a,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; OLIGOMER; BIOLOGICAL MARKER; PROTEIN AGGREGATE;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CELL INCLUSION; CLINICAL EVALUATION; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; ELISA KIT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTREAL COGNITIVE ASSESSMENT; NEUROTOXICITY; PARKINSON DISEASE; SALIVA ANALYSIS; SALIVA LEVEL; UNIFIED PARKINSON DISEASE RATING SCALE; CHEMISTRY; EARLY DIAGNOSIS; METABOLISM; MIDDLE AGED; SALIVA; SOLUBILITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; BIOMARKERS; COHORT STUDIES; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PROTEIN AGGREGATES; SALIVA; SOLUBILITY;

EID: 84962069192     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151156     Document Type: Article

References (45)

1. Lee HJ, Bae EJ, Lee SJ. Extracellular α-synuclein-a novel and crucial factor in Lewy body diseases. Nat Rev Neurol 2014;10:92-98. doi: 10.1038/nrneurol.2013.275 PMID: 24468877
2. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-840. PMID: 9278044
3. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009;8:1150-1157. doi: 10.1016/S1474-4422 (09) 70238-8 PMID: 19909913
4. Fauvet B, Mbefo MK, Fares MB, Desobry C, Michael S, Ardah MT, Tsika E, et al. a-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem 2012;287:15345-15364. doi: 10.1074/jbc. M111.318949 PMID: 22315227
5. Bendor JT, Logan TP, Edwards RH. The function of a-synuclein. Neuron 2013;79:1044-1066. doi: 10. 1016/j.neuron. 2013.09.004 PMID: 24050397
6. Vivacqua G, Casini A, Vaccaro R, Fornai F, Yu S, D'Este L. Different sub-cellular localization of alphasynuclein in the C57BL\6J mouse's central nervous system by two novel monoclonal antibodies. J Chem Neuroanat 2011;41:97-110. doi: 10.1016/j.jchemneu.2010.12.003 PMID: 21172422
7. Kayed R, Head E, Thompson JL, Milton SC, Cotman CW, Glabe CG, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003;300:486-489. PMID: 12702875
8. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol 2011;10:1015-1025. doi: 10.1016/S1474-4422 (11) 70213-7 PMID: 22014436
9. Paleologou KE, Kragh CL, Mann DM, Salem SA, Al-Shami R, Allsop D, et al. Detection of elevated levels of soluble [alpha]-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 2009;132:1093-1101. doi: 10.1093/brain/awn349 PMID: 19155272
10. Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 2002;8:600-606. PMID: 12042811
11. Winner B, Jappeli R, Maji SK, Desplats PA, Boyer L, Aigner S, et al. In vivo demonstration that alphasynuclein oligomers are toxic. Proc Natl Acad Sci USA 2011;108:4194-4199. doi: 10.1073/pnas. 1100976108 PMID: 21325059
12. Roberts HL, Brown DR. Seeking a Mechanism for the Toxicity of Oligomeric α-Synuclein. Biomolecules 2015;5:282-305. doi: 10.3390/biom5020282 PMID: 25816357
13. Tokuda T, Salem SA, Alisop D, Mizuno T, Nakagawa M, Qureshi MM, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006;349:162-166. PMID: 16930553
14. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10:230-240. doi: 10.1016/S1474-4422 (11) 70014-X PMID: 21317042
15. Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, et al. Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord 2011;26:1428-1435. doi: 10.1002/mds.23670 PMID: 21469206
16. Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, El-Agnaf O, et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol 2013;9:131-140. doi: 10.1038/nrneurol.2013.10 PMID: 23419373
17. Phillips RJ, Walter GC, Wilder SL, Baronowsky FA, Powley TL. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease? Neuroscience 2008;153:733-750. doi: 10.1016/j.neuroscience.2008.02.074 PMID: 18407422
18. Grathwohl SA, Steiner JA, Britschgi M, Brundin P. Mind the gut: secretion of alpha-synuclein by enteric neurons. J Neurochem 2013;125:487-490. doi: 10.1111/jnc.12191 PMID: 23448303
19. Visanji NP, Marras C, Kern DS, Al Dakheel A, Gao A, Liu LW, et al. Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology 2015;84:609-616. PMID: 25589666
20. Donadio V, Incensi A, Leta V, Giannoccaro MP, Scaglione C, Martinelli P, et al. Skin nerve α-synuclein deposits: a biomarker for idiopathic Parkinson disease. Neurology 2014;82:1362-1369. doi: 10.1212/WNL.0000000000000316 PMID: 24634456
21. Zange L, Noack C, Hahn K, Stenzel W, Lipp A. Phosphorylated α-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy. Brain 2015;138:2310-2321. doi: 10.1093/brain/awv138 PMID: 26017579
22. Folgoas E, Lebouvier T, Leclair-Visonneau L, Cersosimo MG, Barthelaix A, Derkinderen P, et al. Diagnostic value of minor salivary glands biopsy for the detection of Lewy pathology. Neurosci Lett. 2013;551:62-64. doi: 10.1016/j.neulet.2013.07.016 PMID: 23880024
23. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol 2010;119:703-713. doi: 10.1007/s00401-010-0665-2 PMID: 20229352
24. Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C, et al. Salivary a-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 2010;134:1-5.
25. Al-Nimer MS, Mshatat SF, Abdulla HI. Saliva a-Synuclein and A High Extinction Coefficient Protein: a novel approach in assessment biomarkers of Parkinson's disease. N Am J Med Sci 2014;6:633-637. doi: 10.4103/1947-2714.147980 PMID: 25599051
26. Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW. Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J Clin Neurol 2010;7:215-222.
27. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010;75:1766-1772. doi: 10.1212/WNL.0b013e3181fd613b PMID: 20962290
28. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52. PMID: 2841426
29. Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, et al. EFNS/MDS-ES/ENS recommendations for the diagnosis of Parkinson's disease. Eur J Neurol 2013;20:16-34. doi: 10.1111/ene. 12022 PMID: 23279440
30. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-2653. doi: 10.1002/mds. 23429 PMID: 21069833
31. Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson. Neurology 2009;73:1738-1745. doi: 10.1212/WNL. 0b013e3181c34b47 PMID: 19933974
32. Kaszas B, Kovacs N, Balas I, Kallai J, Aschermann Z, Kerekes Z, et al. Sensitivity and specificity of Addenbrooke's Cognitive Examination, Mattis Dementia Rating Scale, Frontal Assessment Battery and Mini Mental State Examination for diagnosing dementia in Parkinson's disease. Parkinsonism Relat Disord 2012;18:553-556. doi: 10.1016/j.parkreldis.2012.02.010 PMID: 22405839
33. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010;133:713-726. doi: 10.1093/brain/awq008 PMID: 20157014
34. Cersosimo MG, Benarroch EE. Pathological correlates of gastrointestinal dysfunction in Parkinson's disease. Neurobiol Dis. 2012;46:559-564. doi: 10.1016/j.nbd.2011.10.014 PMID: 22048068
35. Breydo L, Wu JW, Uversky VN. A-synuclein misfolding and Parkinson's disease. Biochim Biophys Acta 2012;1822:261-285. doi: 10.1016/j.bbadis.2011.10.002 PMID: 22024360
36. Xilouri M, Brekk OR, Stefanis L. α-Synuclein and protein degradation systems: a reciprocal relationship. Mol Neurobiol 2013;47:537-551. doi: 10.1007/s12035-012-8341-2 PMID: 22941029
37. Hong DP, Han S, Fink AL, Uversky VN. Characterization of the non-fibrillar α-synuclein oligomers. Protein Pept Lett 2011;18:230-240. PMID: 20858207
38. Hall S, Surova Y, Ohrfelt A, Zetterberg H, Lindqvist D, Hansson O. CSF biomarkers and clinical progression of Parkinson disease. Neurology 2015;84:57-63. doi: 10.1212/WNL.0000000000001098 PMID: 25411441
39. Stewart T, Liu C, Ginghina C, Cain KC, Auinger P, Cholerton B, et al. Parkinson Study Group DATATOP Investigators. Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol 2014;184:966-975. doi: 10.1016/j.ajpath.2013.12.007 PMID: 24625392
40. Hu Y, Yu SY, Zuo LJ, Cao CJ, Wang F, Chen ZJ, et al. Parkinson disease with REM sleep behavior disorder: features, α-synuclein, and inflammation. Neurology 2015;84:888-894. doi: 10.1212/WNL. 0000000000001308 PMID: 25663225
41. Unterberger U, Lachmann I, Voigtlander T, Pirker W, Berghoff AS, Flach K, et al. Detection of diseaseassociated α-synuclein in the cerebrospinal fluid: a feasibility study. Clin Neuropathol. 2014;33(5):329-334. PMID: 25131945
42. Maetzler W, Pilotto A, Apel A, Deuschle C, Kuebart G, Heinzel S, et al. In vivo markers of Parkinson's disease and dementia with Lewy bodies: current value of the 5G4 α-synuclein antibody. Acta Neuropathol 2014;128:893-895. doi: 10.1007/s00401-014-1364-1 PMID: 25376537
43. Cersósimo MG, Tumilasci OR, Raina GB, Deuschle C, Kuebart G, Heinzel S, et al. Hyposialorrhea as an early manifestation of Parkinson disease. Auton Neurosci 2009;150:150-151. doi: 10.1016/j. autneu.2009.04.004 PMID: 19419908
44. Tumilasci OR, Cersósimo MG, Belforte JE, Micheli FE, Benarroch EE, Pazo JH. Quantitative study of salivary secretion in Parkinson's disease. Mov Disord 2006;21:660-667. PMID: 16419045
45. Tolosa E, Vilas Rolàn D. Peripheral synuclein tissue markers: a step closer to Parkinson's disease diagnosis. Brain 2015;138:2114-2125.